Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty.

BACKGROUND Recurrent atherosclerotic plaque growth, restenosis, is a significant clinical problem after interventional procedures. Initiation of restenosis involves activation of inflammatory and thrombotic cascades, which are regulated by serine proteinase enzymes and inhibitors. We have investigated the use of a viral serine proteinase inhibitor, SERP-1, to reduce plaque development after primary balloon angioplasty. This is the first experimental report of the use of a viral anti-inflammatory protein for the prevention of atherosclerosis. METHODS AND RESULTS Seventy-four cholesterol-fed rabbits were treated with either local or systemic infusions of SERP-1 protein (or control solutions) after balloon-mediated injury. Sites of SERP-1 infusion in rabbits had dramatically reduced plaque compared with control infusions at the 4-week follow-up. At low-dose infusions (30 to 300 pg), only the primary infusion site had a demonstrable decrease in plaque, whereas at higher-dose infusions (> 3000 pg), a generalized reduction in plaque development was detected. An associated decrease in mononuclear cell infiltration of the arterial wall was detected after SERP-1 infusion within the first 24 hours. Infusion of an active-site mutant of SERP-1 (P1-P1', ala-ala) lacking serine proteinase inhibitory activity failed to prevent plaque growth. CONCLUSIONS Purified SERP-1, a virus-encoded secreted glycoprotein, reduces plaque growth after primary balloon-mediated injury. Plaque development is decreased by inhibition of serine proteinase activity and is associated with a focal reduction in macrophage infiltration immediately after injury. Investigation of serine proteinase inhibitors may provide new insight into the regulation of arterial responses to injury.

[1]  L. Gooding.  Virus proteins that counteract host immune defenses , 1992, Cell.

[2]  A. Gown,et al.  Human atherosclerosis. II. Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions. , 1986, The American journal of pathology.

[3]  P. Libby,et al.  Sustained Activation of Vascular Cells and Leukocytes in the Rabbit Aorta After Balloon Injury , 1993, Circulation.

[4]  A. Marcus,et al.  Vascular transcellular signaling. , 1993, Journal of lipid research.

[5]  J. Tulip,et al.  Development of an avian model for restenosis. , 1996, Atherosclerosis.

[6]  S. Ellis,et al.  Arterial injury and the enigma of coronary restenosis. , 1992, Journal of the American College of Cardiology.

[7]  P. Weissberg,et al.  Approaches to the development of selective inhibitors of vascular smooth muscle cell proliferation. , 1993, Cardiovascular research.

[8]  R. Ross,et al.  Rous-Whipple Award Lecture. Atherosclerosis: a defense mechanism gone awry. , 1993, The American journal of pathology.

[9]  K. Forsyth,et al.  Endothelial serpins—protectors of the vasculature? , 1994, Clinical and experimental immunology.

[10]  D. Waters,et al.  Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. , 1994, Circulation.

[11]  K. Karsch,et al.  Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. , 1990, Circulation research.

[12]  M. Leon,et al.  Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. , 1994, Science.

[13]  E J Topol,et al.  The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. , 1992, Journal of the American College of Cardiology.

[14]  B. W. Griffiths,et al.  Comparative studies of Iodo-bead and chloramine-T methods for the radioiodination of human alpha-fetoprotein. , 1984, Journal of immunological methods.

[15]  M. Spriggs,et al.  One step ahead of the game: viral immunomodulatory molecules. , 1996, Annual review of immunology.

[16]  A. Bradbury,et al.  Role of the leucocyte in the pathogenesis of vascular disease , 1993, The British journal of surgery.

[17]  G. McFadden,et al.  Modulation of cytokine networks by poxvirus: the myxoma virus model , 1994 .

[18]  M. Reidy,et al.  The Role of Plasminogen Activation in Smooth Muscle Cell Migration after Arterial Injury , 1992, Annals of the New York Academy of Sciences.

[19]  D. Wishart,et al.  Myxoma virus and malignant rabbit fibroma virus encode a serpin-like protein important for virus virulence. , 1990, Virology.

[20]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[21]  G. Smith.  Virus strategies for evasion of the host response to infection. , 1994, Trends in microbiology.

[22]  G. McFadden,et al.  SERP-1, a poxvirus-encoded serpin, is expressed as a secreted glycoprotein that inhibits the inflammatory response to myxoma virus infection. , 1997, Advances in experimental medicine and biology.

[23]  M. Lopes-Virella,et al.  Immunological and microbiological factors in the pathogenesis of atherosclerosis. , 1985, Clinical immunology and immunopathology.

[24]  J. Gillespie,et al.  Virus-Induced Cholesterol Crystals , 1973, Science.

[25]  Y. Watanabe.  Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL-rabbit). , 1980, Atherosclerosis.

[26]  J. Cacchione,et al.  Local intramural drug delivery using an infusion balloon following angioplasty in normal and atherosclerotic vessels. , 1994, Catheterization and cardiovascular diagnosis.

[27]  G. Gibbons,et al.  The emerging concept of vascular remodeling. , 1994, The New England journal of medicine.

[28]  G. McFadden,et al.  SERP1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. , 1993, Virology.

[29]  K. Kent,et al.  The Effect of Porous Infusion Balloon‐Delivered Angiopeptin on Myointimal Hyperplasia After Balloon Injury in the Rabbit , 1993, Circulation.

[30]  S. Thung,et al.  Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. , 1990, Journal of the American College of Cardiology.

[31]  P. Carmeliet,et al.  Physiological consequences of loss of plasminogen activator gene function in mice , 1994, Nature.

[32]  D. Lomas,et al.  Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor. , 1993, The Journal of biological chemistry.

[33]  D. Altieri.  Proteases and protease receptors in modulation of leukocyte effector functions , 1995, Journal of leukocyte biology.

[34]  J. Cooke,et al.  Vascular Biology and Medicine in the 1990s: Scope, Concepts, Potentials, and Perspectives , 1993, Circulation.

[35]  A. Becker,et al.  Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. , 1994, Circulation.

[36]  G. McFadden.  Viroceptors, virokines and related immune modulators encoded by DNA viruses , 1995 .